Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Chang Chun, China Clinical Trials

A listing of Chang Chun, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (25) clinical trials

A Study of Lorlatinib in ALK Inhibitor Treated ALK Positive NSCLC in China

This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy. (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor. (in Cohort 2) Disease progression after one ALK …

Phase

2.18 miles

Learn More »

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

This is an open-label, single-arm, two-stage, multi-center, phase 2 study in patients with relapsed/refractory follicular lymphoma (FL) who have received at least two prior standard therapy lines.

Phase

2.18 miles

Learn More »

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With RET Activation

The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Phase

2.18 miles

Learn More »

A Study of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion

This is a Phase 2, open-label, single-arm, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) in the presence of 17p deletion.

Phase

3.46 miles

Learn More »

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

Evidence shows independent associations between hyperuricaemia and the risk of hypertension, myocardial infarction, chronic kidney disease (CKD), type 2 diabetes, heart failure, and metabolic syndrome, including obesity Furthermore, gout, an inflammatory arthritis caused by deposition of monosodium urate crystals in joints, is associated with an increased risk of all-cause death, …

Phase

3.46 miles

Learn More »

Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Phase

3.46 miles

Learn More »

Effects of Yangxinshi Pills on the Exercise Tolerance of the Patients With Coronary Heart Disease

90 outpatients with clear diagnosis of coronary heart diseases will be recruited in the trial and randomized into two group. One group are treated with Yangxinshi pills (provided by Qingdao Growtful Pharmaceutical Co., Ltd.) plus conventional medicine, the other group are treated with placebo plus conventional medicine. The primary end …

Phase

3.46 miles

Learn More »

NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.

The small-cell lung cancer (SCLC) is very sensitive to the standard-of-care first-line chemotherapy and/or radiotherapy, but it will ultimately progress or relapse and develop early resistance to conventional treatments. No effective maintenance therapy except for wath and wait after first-line therapy at present. NK cells constitute the major component of …

Phase

3.46 miles

Learn More »

The Efficacy Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled, dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and planned percutaneous coronary intervention PCI will be randomized after informed consent, in a 1:1:1:1 ratio to the following treatment groups: Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for …

Phase

5.05 miles

Learn More »

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

The study is a single-arm, multi-center, open-label clinical trial. The study aims to expand the sample size based on the fixed dose recommended by the results of previous dose exploration studies in order to further evaluate the study drug's efficacy and safety with overall objective tumor response rate (ORR) as …

Phase

5.23 miles

Learn More »